Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side-effects.

Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight loss effects the drug is known for.

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s tirzepati | An observational study from Washington University in St.

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines, according to a research letter published on Friday.

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have to negotiate, but if they don’t, they face fines or the possible end of Medicare reimbursements.

with a 20.4% reduction in weight in the REDEFINE 1 study over 68 weeks that fell short of Novo Nordisk's hope of a 25% loss. At the least, the new 7.2mg results point to scope for hiking the ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than adults receiving semaglutide 2.4 mg, according to top-line results from the STEP UP phase 3b trial.

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching $39.3 billion, thanks to its portfolio of potent drugs for cardiometabolic illnesses like diabetes and obesity.

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the company said semaglutide 7.2 milligram (mg) injections over a 72-week period resulted in an average weight loss of 20.7%, better than the 17.5% weight loss achieved in a prior trial of semaglutide 2.4 mg injections.

Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. Pharma giants Novo Nordisk and Eli Lilly look to be the main benefactors of GLP-1 medications turning into a “catch-all pill,